Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Salutaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Salutaxel overview
Salutaxel is under development for the treatment of advanced breast cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, prostate cancer, head and neck squamous cell carcinoma, ovarian cancer, pancreatic cancer, colorectal cancer and melanoma. It is administered by intravenous route. The drug candidate comprises of docetaxel conjugated with muramyl dipeptide (MDP) analogue via succinic linker.
Shenzhen Salubris Pharmaceuticals overview
Shenzhen Salubris Pharmaceuticals (Salubris) focuses on the research, development, manufacture and distribution of pharmaceutical products. The company’s pipeline products include sacubitril allisartan calcium (S086), allisartan isoproxilamlodipine besylate tablets, allisartan isoproxilindapamide sustained-release tablets, enarodustat (SAL0951), SAL0104, SAL007, SAL003, SAL056P, SAL001, SAL02, fotagliptin, SAL015 and SAL0112, among others. Salubris is investigating small molecules and biological therapeutics for the treatment of metabolic, oncology and also bone diseases. The company also develops interventional medical devices for cardiology, cerebrovascular, structural heart and peripheral vascular disease areas. It operates in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, Guangdong, China.
For a complete picture of Salutaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
